文献速递青光眼

英国青光眼治疗研究中视野恶化的危险因素

Risk Factors for Visual Field Deterioration in the United Kingdom Glaucoma Treatment Study.
PubMed 文献 · Ophthalmology · 2020-06-12

结果显示拉坦前列素使视野恶化风险降低58%,双眼患病、较高基线眼压和视盘出血是视野恶化的危险因素,而吸烟史似乎具有保护作用。

要点

  • 拉坦前列素治疗使视野恶化风险降低58%(HR 0.42,95%CI 0.27-0.67,P=0.001)。
  • 双眼患病(HR 1.59)、较高基线眼压(每mmHg HR 1.07)和视盘出血(HR 2.08)是视野恶化的危险因素。
  • 吸烟史(当前或既往)与视野恶化风险降低相关(HR 0.59,95%CI 0.37-0.93,P=0.023)。

核心结论

  • 在UKGTS中,拉坦前列素治疗使视野恶化风险减半。
  • 双眼患病、较高眼压和视盘出血被确认为视野恶化的危险因素;吸烟史似乎对视野恶化有保护作用。

研究设计与样本

  • 随机、双盲、安慰剂对照的多中心试验。

主要发现

  • 拉坦前列素治疗使视野恶化风险降低58%(HR 0.42;95%CI 0.27-0.67;P=0.001)。
  • 双眼患病与视野恶化风险升高相关(HR 1.59;95%CI 1.02-2.50;P=0.041)。
  • 较高基线眼压与视野恶化风险升高相关(每mmHg HR 1.07;95%CI 1.02-1.12;P=0.008)。
  • 第1次访视时视盘出血与视野恶化风险升高相关(HR 2.08;95%CI 1.07-4.04;P=0.030)。
  • 吸烟(当前或既往)与视野恶化风险降低相关(HR 0.59;95%CI 0.37-0.93;P=0.023)。

关键数值与推荐

  • 采用引导进展分析模式偏差图确定视野恶化。
  • 使用Cox回归计算风险比(HR)及95%置信区间(CI),并考虑中心内相关性。
  • 模型选择基于单变量分析中P≤0.2的变量进行向后逐步选择;与基线值共线性的随访变量未保留在最终模型中。

临床怎么用

  • 对于开放角型青光眼患者,拉坦前列素治疗可显著降低视野恶化风险。
  • 双眼患病、较高基线眼压和视盘出血提示视野恶化风险较高,可能需要更密切监测。
  • 吸烟史与视野恶化风险降低相关,但需谨慎解读,不应鼓励吸烟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The United Kingdom Glaucoma Treatment Study (UKGTS) investigated the visual field (VF)-preserving effect of medical treatment in open-angle glaucoma (OAG). The objective of this analysis was to identify risk factors associated with VF deterioration. DESIGN: Randomized, double-masked, placebo-controlled multicenter trial. PARTICIPANTS: Five hundred sixteen participants with previously untreated OAG were recruited prospectively in 10 United Kingdom centers. METHODS: Eligibility criteria were modeled on those for the Early Manifest Glaucoma Trial. Study participants were randomized to either latanoprost 0.005% or placebo eye drops. The observation period was 2 years and involved, among other procedures, VF testing and intraocular pressure (IOP) measurement at 11 scheduled visits, with clustering of tests at baseline, 18 months, and 24 months. Guided progression analysis pattern deviation maps were used to determine VF deterioration. Cox regression was used to compute the hazard ratios (HRs) and respective 95% confidence intervals (CIs) while accounting for the correlation within sites. Model selection was guided by backward stepwise selection conducted on the model containing all variables that were significant at the 0.2 level in the univariate analysis. Follow-up variables that showed collinearity with baseline values were not retained in the final model. MAIN OUTCOME MEASURE: Time to VF deterioration. RESULTS: Treatment with latanoprost reduced the HR, for VF deterioration by 58% (HR, 0.42; 95% CI, 0.27-0.67; P = 0.001). Factors associated with deterioration were bilateral disease (HR, 1.59 for yes vs. no; 95% CI, 1.02-2.50; P = 0.041), higher baseline IOP (HR, 1.07 per mmHg; 95% CI, 1.02-1.12; P = 0.008), and disc hemorrhage at visit 1 (HR, 2.08; 95% CI, 1.07-4.04; P = 0.030). Smoking (current or previous) was associated with a reduced HR, for VF deterioration (HR, 0.59; 95% CI, 0.37-0.93; P = 0.023). No other evaluated factors were found to be statistically significant in the multivariable analysis. CONCLUSIONS: In the UKGTS, treatment with latanoprost halved VF deterioration risk. Bilateral disease, higher IOP, and disc hemorrhage were confirmed as risk factors for deterioration; smoking history seemed to be protective against VF deterioration.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Founti P, Bunce C, Khawaja AP, et al. Risk Factors for Visual Field Deterioration in the United Kingdom Glaucoma Treatment Study. Ophthalmology. 2020. PMID: 32540325. doi:10.1016/j.ophtha.2020.06.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。